Compare MED & SRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MED | SRZN |
|---|---|---|
| Founded | 1980 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.6M | 117.8M |
| IPO Year | N/A | N/A |
| Metric | MED | SRZN |
|---|---|---|
| Price | $10.88 | $20.46 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $16.50 | ★ $38.50 |
| AVG Volume (30 Days) | ★ 200.3K | 118.7K |
| Earning Date | 11-03-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $429,695,000.00 | $3,604,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $450.87 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.36 | $5.90 |
| 52 Week High | $21.98 | $20.47 |
| Indicator | MED | SRZN |
|---|---|---|
| Relative Strength Index (RSI) | 37.36 | 78.88 |
| Support Level | $10.72 | $14.94 |
| Resistance Level | $11.12 | $16.75 |
| Average True Range (ATR) | 0.33 | 1.21 |
| MACD | 0.07 | 0.58 |
| Stochastic Oscillator | 48.37 | 99.87 |
Medifast Inc is a old health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a simple, yet comprehensive approach to address obesity and support a healthy life. OPTAVIA provides unparalleled coaching support along with community, tailored nutrition and healthy habits, and empowers people to master their weight loss journey through each stage of life. The company has access to GLP-1 medications where clinically appropriate. Medifast remains committed to its mission of offering Lifelong Transformation, Making a Healthy Lifestyle Second Nature.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).